Targeting RIPK1 to improve pain treatment without addiction
Inhibiting RIPK1 with Necrostatin-1 for Safe and Effective Pain Treatment
This study is exploring a new way to help people with chronic pain by testing a special compound that targets a protein linked to pain and inflammation in the brain, aiming to offer a safer treatment option that doesn't lead to addiction.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10507932 on NIH RePORTER |
What this research studies
This research investigates a new approach to treating chronic pain by inhibiting a protein called RIPK1, which is linked to neuroinflammation and pain processing. The study aims to develop a compound called Necrostatin-1 that can cross the blood-brain barrier and potentially reduce pain without the risk of addiction. By examining how RIPK1 contributes to pain in the brain, the research seeks to provide a safer alternative for pain management. Patients may benefit from this innovative treatment if it proves effective in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals suffering from chronic pain, particularly those with neuropathic pain conditions.
Not a fit: Patients who do not experience chronic pain or have conditions unrelated to neuropathic pain may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer pain management options that minimize the risk of addiction.
How similar studies have performed: Other research has shown promise in targeting similar pathways for pain management, suggesting that this approach could be effective.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Shen, Shiqian — Massachusetts General Hospital
- Study coordinator: Shen, Shiqian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.